

Remdesivir Use Compared to Supportive Care in Hospitalized Patients with Severe COVID-

19:

A Single-Center Experience

Markos Kalligeros¹, Karen T. Tashima^{1,*}, Evangelia K. Mylona¹, Natasha Rybak¹, Timothy P. Flanigan¹, Dimitrios Farmakiotis¹, Curt G. Beckwith¹, Martha Sanchez¹, Marguerite Neill¹, Jennie E. Johnson¹, Joseph M. Garland¹, Su Aung¹, Katrina M. Byrd¹, Thomas O'Brien¹, Aakriti Pandita¹, Jad Aridi¹, Raul Macias Gil¹, Jerome Larkin¹, Fadi Shehadeh¹, Eleftherios Mylonakis^{1,*}

Supplementary Appendix

Affiliation: Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, RI, USA,


Correspondence to: *Karen T. Tashima, 180 Corliss St. Suite F, The Miriam Hospital, Providence, RI 02904

KTashima@Lifespan.org

*Eleftherios Mylonakis, 593 Eddy Street, 328/330 POB Providence, Rhode Island 02903, USA. emylonakis@lifespan.org

Summary: Patients on remdesivir had lower in hospital mortality, albeit not significant, and the use of remdesivir did not increase the risk for AKI.

Supplementary Figure 1 - Kaplan Meier survival estimates of 28-days in-hospital death



Supplementary Table 1. Characteristics of patients enrolled in the RDV trial arm

	Total	Included	Excluded	p-value
	N=145	N=99	N=46	
Age	60.00 (52.00-70.00)	58.00 (50.00-68.00)	62.00 (58.00-76.00)	0.021
Gender				0.78
Female	45 (31.0%)	30 (30.3%)	15 (32.6%)	
Male	100 (69.0%)	69 (69.7%)	31 (67.4%)	
Race				0.72
Asian	1 (0.7%)	1 (1.0%)	0 (0.0%)	
Black or African American	17 (11.7%)	10 (10.1%)	7 (15.2%)	
Hispanic or Latino	68 (46.9%)	48 (48.5%)	20 (43.5%)	
Other/Unknown	9 (6.2%)	5 (5.1%)	4 (8.7%)	
White or Caucasian	50 (34.5%)	35 (35.4%)	15 (32.6%)	
Hypertension	55 (37.9%)	32 (32.3%)	23 (50.0%)	0.041
HeartDisease	23 (15.9%)	14 (14.1%)	9 (19.6%)	0.41
Chronic pulmonary disease	15 (10.3%)	11 (11.1%)	4 (8.7%)	0.66
Diabetes	43 (29.7%)	28 (28.3%)	15 (32.6%)	0.60
Renal failure	4 (2.8%)	3 (3.0%)	1 (2.2%)	0.77
Liver disease	5 (3.4%)	4 (4.0%)	1 (2.2%)	0.57
Obesity	58 (40.0%)	43 (43.4%)	15 (32.6%)	0.22
Days between Symptom Onset and Admission	6.00 (3.00-8.00)	6.00 (3.00-8.00)	4.00 (2.00-7.00)	0.14
Days between Symptom Onset and initiation of RDV	8.00 (5.00-10.00)	7.00 (5.00-10.00)	9.00 (6.00-12.00)	0.008
Baseline Oxygen				0.76
Invasive Mechanical Ventilation	26 (17.9%)	19 (19.2%)	7 (15.2%)	
Low Flow Supplemental Oxygen	72 (49.7%)	48 (48.5%)	24 (52.2%)	
NIPPV or HFNC	38 (26.2%)	27 (27.3%)	11 (23.9%)	
Room Air	9 (6.2%)	5 (5.1%)	4 (8.7%)	
Hydroxychloroquine	11 (7.6%)	5 (5.1%)	6 (13.0%)	0.091
Convalescent plasma	9 (6.2%)	3 (3.0%)	6 (13.0%)	0.020
Weighted Elixhauser index (van Walraven)				0.006
<0	36 (24.8%)	29 (29.3%)	7 (15.2%)	
0	42 (29.0%)	34 (34.3%)	8 (17.4%)	
1-4	18 (12.4%)	9 (9.1%)	9 (19.6%)	
>=5	49 (33.8%)	27 (27.3%)	22 (47.8%)	
ICU admission	81 (55.9%)	51 (51.5%)	30 (65.2%)	0.12
Intubation	45 (31.0%)	28 (28.3%)	17 (37.0%)	0.29

Comorbidities were estimated using ICD-10 codes according to the Elixhauser Comorbidity Index

*At least 1 dose of dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone, or prednisone